AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24728866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study 23870614 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg administered enterally for 14 days
Number of subjects: 0
Study 23870614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19232762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrates
Number of subjects: 11590
Study 19232762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11590
Study 18208909 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (7 days treatment)
Number of subjects: 0
Study 18208909 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (7 days treatment)
Number of subjects: 0
Study 18208909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16826486 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV-TV vaccine
Number of subjects: 510
Study 16826486 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-TV vaccine
Number of subjects: 510
Study 16826486 — intervention group
Group type: COMPARATOR
Intervention: Both vaccines
Number of subjects: 510
Study 12734133 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing (DDD) with rate drop response
Number of subjects: 100
Study 12734133 — intervention group
Group type: COMPARATOR
Intervention: Only sensing without pacing (ODO)
Number of subjects: 100
Study 11518325 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactooligosaccharide (8 g per day)
Number of subjects: 0
Study 11518325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis Bb-12 (3 x 10^10 cfu per day)
Number of subjects: 0
Study 11518325 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactooligosaccharide and Bifidobacterium lactis Bb-12
Number of subjects: 0
Study 9629993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg tablet (test formulation)
Number of subjects: 24
Study 9629993 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg tablet (reference formulation)
Number of subjects: 24
Study 8165742 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg body weight over 3 days)
Number of subjects: 152
Study 8165742 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine/pyrimethamine (standard doses)
Number of subjects: 152
Study 3262219 — intervention group
Group type: EXPERIMENTAL
Intervention: Social pressure resistance training program
Number of subjects: 0
Study 3262219 — intervention group
Group type: COMPARATOR
Intervention: Affective education program
Number of subjects: 0
Study 31006271 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep quality measured by General Sleep Disturbance Scale (GSDS) at 6 weeks postpartum
Number of subjects: 217
Study 31006271 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of sleep as a 'small' or 'big' problem at 6 weeks postpartum
Number of subjects: 217
Study 31006271 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphic sleep measures
Number of subjects: 217
Study 29525345 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodophor‐impregnated adhesive drapes
Number of subjects: 101
Study 29525345 — intervention group
Group type: COMPARATOR
Intervention: No adhesive drapes (Control)
Number of subjects: 101
Study 28778110 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIKES training program based on video reviews, involving discussions of simulated encounters communicating perinatal loss.
Number of subjects: 44
Study 28778110 — intervention group
Group type: COMPARATOR
Intervention: Control group received no training during the study period but were offered training sessions afterward.
Number of subjects: 44
Study 25637195 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety decision aid intervention
Number of subjects: 340
Study 25637195 — intervention group
Group type: COMPARATOR
Intervention: Usual safety planning control website
Number of subjects: 340
Study 24356654 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care pathway for hip fracture patients
Number of subjects: 0
Study 24356654 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 20800123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried plums
Number of subjects: 26
Study 20800123 — intervention group
Group type: COMPARATOR
Intervention: Low-fat cookies
Number of subjects: 26
Study 19140647 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific strategy instructions designed to encourage semantic, integrative encoding
Number of subjects: 0
Study 19140647 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition that encouraged time and attention to encoding but allowed participants to choose their own strategy
Number of subjects: 0
Study 17153903 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telehealth intervention
Number of subjects: 0
Study 17153903 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial telehealth systems
Number of subjects: 0
Study 17153903 — intervention group
Group type: EXPERIMENTAL
Intervention: Research projects by University of Minnesota
Number of subjects: 0
Study 12541152 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography with modification of hemodynamic conditions (group I)
Number of subjects: 55
Study 12541152 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography with modification of hemodynamic conditions (group II)
Number of subjects: 55
Study 12541152 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography with LV volumes method (group I)
Number of subjects: 55
Study 12541152 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography with LV volumes method (group II)
Number of subjects: 55
Study 12541152 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography with Doppler method (group II)
Number of subjects: 55
Study 10759650 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 228
Study 10759650 — intervention group
Group type: COMPARATOR
Intervention: Untreated (observed) control group
Number of subjects: 228
Study 8816204 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms
Number of subjects: 16
Study 8816204 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 400 micrograms
Number of subjects: 16
Study 8816204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1425528 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction programme (6-week course led by public health nurses)
Number of subjects: 93
Study 1425528 — intervention group
Group type: COMPARATOR
Intervention: Control group (no weight reduction instruction)
Number of subjects: 93
Study 1425528 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 93
Study 30957394 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-inflated negative binomial regression model
Number of subjects: 0
Study 30957394 — intervention group
Group type: COMPARATOR
Intervention: Conventional normal NLME regression models
Number of subjects: 0
Study 29790635 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg odourless garlic tablet
Number of subjects: 76
Study 29790635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 26818586 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (ACT)
Number of subjects: 9
Study 26818586 — intervention group
Group type: COMPARATOR
Intervention: Cold-water immersion (CWI)
Number of subjects: 9
Study 23801526 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home supervised exercise intervention (n=10)
Number of subjects: 21
Study 23801526 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized healthful lifestyle advice
Number of subjects: 21
Study 23801526 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=11)
Number of subjects: 21
Study 22072492 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589), oral administration
Number of subjects: 13
Study 19880433 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Qigong (MQ)
Number of subjects: 162
Study 19880433 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 162
Study 17685673 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 15 repetitions maximum (RM)
Number of subjects: 61
Study 17685673 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 9RM
Number of subjects: 61
Study 17685673 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 6RM
Number of subjects: 61
Study 17685673 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 61
Study 17685673 — intervention group
Group type: EXPERIMENTAL
Intervention: All training groups (combined)
Number of subjects: 61
Study 15578202 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric endurance at different percentages of maximal isometric contraction (MVC)
Number of subjects: 12
Study 15578202 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoelectrical fatigability (muscle fibre conduction velocity - CV)
Number of subjects: 12
Study 15578202 — intervention group
Group type: EXPERIMENTAL
Intervention: Median frequency (MDF) of the surface electromyogram (sEMG) of the biceps brachii
Number of subjects: 12
Study 15578202 — intervention group
Group type: EXPERIMENTAL
Intervention: Torque-velocity curve assessed by maximal isokinetic contractions
Number of subjects: 12
Study 12137601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day
Number of subjects: 283
Study 10438996 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg for at least a month before FSH stimulation)
Number of subjects: 20
Study 10438996 — intervention group
Group type: COMPARATOR
Intervention: FSH stimulation alone (Control)
Number of subjects: 20
Study 7492894 — intervention group
Group type: EXPERIMENTAL
Intervention: Superbrush (newly designed toothbrush)
Number of subjects: 30
Study 7492894 — intervention group
Group type: COMPARATOR
Intervention: Single-headed toothbrush (control)
Number of subjects: 30
Study 2312778 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol controlled release tablets 100 mg CR/ZOK
Number of subjects: 10
Study 2312778 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol conventional tablets 100 mg (CT)
Number of subjects: 10
Study 2312778 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg (ATL)
Number of subjects: 10
Study 2312778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7000220 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrinolytic therapy
Number of subjects: 100
Study 7000220 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antifibrinolytic therapy)
Number of subjects: 100
Study 30987588 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of intertrigo
Number of subjects: 223
Study 30987588 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 223
Study 30987588 — intervention group
Group type: EXPERIMENTAL
Intervention: Care dependency in bathing activities
Number of subjects: 223
Study 30987588 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity, sex, and skin functional parameters
Number of subjects: 223
Study 27546524 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 50
Study 27546524 — intervention group
Group type: COMPARATOR
Intervention: Topical estriol treatment (0.5 mg estriol ovules for 8 weeks)
Number of subjects: 50
Study 27546524 — intervention group
Group type: COMPARATOR
Intervention: Topical estriol treatment
Number of subjects: 50
Study 25849109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) with noninvasive positive pressure ventilation
Number of subjects: 55
Study 23195924 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized methadone dosages over 100 mg/day with voucher-based cocaine-targeted contingency management (CM)
Number of subjects: 58
Study 23195924 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose increase from 70 mg/day to 100 mg/day
Number of subjects: 58
Study 21950153 — intervention group
Group type: EXPERIMENTAL
Intervention: New pharmaceutical equivalent tablet formulation containing 500 mg of SAQ mesylate
Number of subjects: 40
Study 21950153 — intervention group
Group type: COMPARATOR
Intervention: Innovator film coated tablet formulation
Number of subjects: 40
Study 19703625 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (Imprint 3) - VPS material with heavy-body (HB) and light-body (LB) viscosities
Number of subjects: 20
Study 19703625 — intervention group
Group type: COMPARATOR
Intervention: Control group (Aquasil Ultra) - Standard VPS with medium-body (MB) and light-body (LB) viscosities
Number of subjects: 20
Study 19703625 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Experimental and Control)
Number of subjects: 20
Study 19703625 — intervention group
Group type: COMPARATOR
Intervention: Control group (Aquasil Ultra)
Number of subjects: 20
Study 19703625 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (Imprint 3)
Number of subjects: 20
Study 17107988 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone 200 microg plus formoterol 12 microg b.i.d. via pMDI
Number of subjects: 219
Study 17107988 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 400 microg plus formoterol 12 microg b.i.d. via DPI
Number of subjects: 219
Study 17107988 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 219
Study 15041601 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg (H1)
Number of subjects: 108
Study 15041601 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg (H2)
Number of subjects: 108
Study 15041601 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 108
Study 11734230 — intervention group
Group type: EXPERIMENTAL
Intervention: DiaPep277 (1 mg p277 and 40 mg mannitol in vegetable oil)
Number of subjects: 35
Study 11734230 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mannitol in vehicle)
Number of subjects: 35
Study 11734230 — intervention group
Group type: EXPERIMENTAL
Intervention: DiaPep277
Number of subjects: 35
Study 11734230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11734230 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 9408726 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8482988 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg Statil (Ponalrestat)
Number of subjects: 34
Study 8482988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 3691679 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised adrenaline (1 mg)
Number of subjects: 18
Study 3691679 — intervention group
Group type: COMPARATOR
Intervention: Nebulised salbutamol (2.5 mg)
Number of subjects: 18
Study 31125296 — intervention group
Group type: EXPERIMENTAL
Intervention: RHIIT programme
Number of subjects: 20
Study 31125296 — intervention group
Group type: COMPARATOR
Intervention: Standard programme
Number of subjects: 20
Study 28394491 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic dose of deferiprone (33 mg/kg)
Number of subjects: 50
Study 28394491 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratherapeutic dose of deferiprone (50 mg/kg)
Number of subjects: 50
Study 28394491 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (positive control)
Number of subjects: 50
Study 28394491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28211094 — intervention group
Group type: EXPERIMENTAL
Intervention: EGD-colonoscopy
Number of subjects: 209
Study 25279959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose intensified hypofractionated intensity-modulated radiotherapy (IMRT) with synchronous cetuximab
Number of subjects: 27
Study 23295834 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0
Study 23295834 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic normothermia
Number of subjects: 0
Study 21621801 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate natural fructose diet (50-70 g/d)
Number of subjects: 131
Study 21621801 — intervention group
Group type: COMPARATOR
Intervention: Low-fructose diet (<20 g/d)
Number of subjects: 131
Study 21621801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 131
Study 18993147 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 10001
Study 18993147 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 10001
Study 16538688 — intervention group
Group type: EXPERIMENTAL
Intervention: EVS closure device
Number of subjects: 362
Study 16538688 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 362
Study 15273178 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlogenzym (rutoside, bromelain, and trypsin)
Number of subjects: 721
Study 15273178 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain/Trypsin
Number of subjects: 721
Study 15273178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 721
Study 15273178 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlogenzym
Number of subjects: 721
Study 15273178 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypsin
Number of subjects: 721
Study 15273178 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlogenzym (in subgroup without Caligamed brace)
Number of subjects: 721
Study 11122832 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies
Number of subjects: 0
Study 11122832 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radioimmunotherapy
Number of subjects: 0
Study 11122832 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted alpha particle therapy
Number of subjects: 0
Study 11122832 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-drug conjugates and immunotoxins
Number of subjects: 0
Study 9314641 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine 675 mg/day
Number of subjects: 216
Study 9314641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 8142985 — intervention group
Group type: EXPERIMENTAL
Intervention: Families with a child conceived by assisted conception (in vitro fertilization and donor insemination)
Number of subjects: 0
Study 8142985 — intervention group
Group type: COMPARATOR
Intervention: Control group of families with a naturally conceived child
Number of subjects: 0
Study 8142985 — intervention group
Group type: COMPARATOR
Intervention: Control group of adoptive families
Number of subjects: 0
Study 3569230 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g of glucose (trial G)
Number of subjects: 6
Study 3569230 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g of fructose (trial F)
Number of subjects: 6
Study 3569230 — intervention group
Group type: COMPARATOR
Intervention: 150 ml of a sweetened placebo (trial C)
Number of subjects: 6
Study 30587441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally daily
Number of subjects: 111
Study 30587441 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel 80 mg/m2 given 3 out of 4 weeks
Number of subjects: 111
Study 27487463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin eye drops administered the day before IVI (four times)
Number of subjects: 92
Study 27487463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin administered one hour before IVI (every 15 minutes)
Number of subjects: 92
Study 27487463 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of ofloxacin both one day and one hour before IVI (eight doses)
Number of subjects: 92
Study 26496309 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 45
Study 26496309 — intervention group
Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 45
Study 23712603 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) in social context (SOC)
Number of subjects: 44
Study 23712603 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (0.8 g/kg) in isolated context (ISO)
Number of subjects: 44
Study 23712603 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo in social context (SOC)
Number of subjects: 44
Study 23712603 — intervention group
Group type: COMPARATOR
Intervention: Placebo in isolated context (ISO)
Number of subjects: 44
Study 23712603 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) in social context (SOC) with partner receiving alcohol
Number of subjects: 44
Study 21442198 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 100
Study 21442198 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 100
Study 19135998 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (nitazoxanide 500 mg twice daily, peginterferon alfa‐2a 180 microg once weekly, ribavirin 1000‐1200 mg/day)
Number of subjects: 96
Study 19135998 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide plus peginterferon alfa‐2a
Number of subjects: 96
Study 19135998 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (peginterferon alfa‐2a and ribavirin for 48 weeks)
Number of subjects: 96
Study 17763706 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational videotape intervention
Number of subjects: 325
Study 17763706 — intervention group
Group type: COMPARATOR
Intervention: Control group (no videotape)
Number of subjects: 325
Study 15033496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy (DBT) inpatient program
Number of subjects: 50
Study 15033496 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (treatment as usual)
Number of subjects: 50
Study 15033496 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT inpatient program
Number of subjects: 50
Study 11534341 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid from a two drugs Fixed Dose Combination (FDC)
Number of subjects: 12
Study 11534341 — intervention group
Group type: COMPARATOR
Intervention: Separate formulation of isoniazid
Number of subjects: 12
Study 9537453 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon alfa-n1
Number of subjects: 1071
Study 9537453 — intervention group
Group type: COMPARATOR
Intervention: Recombinant interferon alfa-2b
Number of subjects: 1071